Tyrosine kinase inhibitors as cancer therapy

被引：6
|
作者：
Nichols, GL
机构：
[1] Columbia Univ Coll Phys & Surg, Dept Med, Div Hematol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, Div Oncol, New York, NY 10032 USA
来源：
CANCER INVESTIGATION | 2003年 / 21卷 / 05期
关键词：
tyrosine kinases; signal transduction; tyrosine kinase inhibitors; cancer therapy;
D O I：
10.1081/CNV-120023774
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：758 / 771
页数：14
相关论文
共 50 条
  • [31] Emerging tyrosine kinase inhibitors for esophageal cancer
    Ku, Geoffrey Y.
    Ilson, David H.
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (02) : 219 - 230
  • [32] Tyrosine kinase inhibitors to treat liver cancer
    Huynh, Hung
    EXPERT OPINION ON EMERGING DRUGS, 2010, 15 (01) : 13 - 26
  • [33] EGFR tyrosine kinase inhibitors in the treatment of cancer
    Barker, AJ
    MEDICINAL CHEMISTRY INTO THE MILLENNIUM, 2001, (264): : 140 - 147
  • [34] Protein tyrosine kinase inhibitors in cancer treatment
    Traxler, PM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (06) : 571 - 588
  • [35] Fasting plus tyrosine kinase inhibitors in cancer
    Caffa, Irene
    Longo, Valter D.
    Nencioni, Alessio
    AGING-US, 2015, 7 (12): : 1026 - 1027
  • [36] Receptor tyrosine kinase inhibitors in thyroid cancer
    Castellone, Maria Domenica
    Carlomagno, Francesca
    Salvatore, Giuliana
    Santoro, Massimo
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 22 (06) : 1023 - 1038
  • [37] Sequential Therapy with tyrosine kinase inhibitors are clinically meaningful
    Jones, Jon
    AKTUELLE UROLOGIE, 2009, 40 (05) : 271 - 272
  • [38] Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
    Hamdi, Amir Imran Faisal
    How, Soon Hin
    Islam, Mohammad Kaisarul
    Lim, Jonathan Chee Woei
    Stanslas, Johnson
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1309 - 1323
  • [39] Recent Advances in Boosting EGFR Tyrosine Kinase Inhibitors-Based Cancer Therapy
    Pan, Qingqing
    Lu, Yao
    Xie, Li
    Wu, Di
    Liu, Rong
    Gao, Wenxia
    Luo, Kui
    He, Bin
    Pu, Yuji
    MOLECULAR PHARMACEUTICS, 2023, : 829 - 852
  • [40] The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy
    Peng, Yanjing
    Tan, Jinjing
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (08):
12345